ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
22 announcements with these filters
Procter & Gamble Health informed shareholders about an extended SEBI-mandated special window for re-lodging rejected physical share transfer requests until February 4, 2027.
Procter & Gamble Health shareholders approved the re-appointment of Mr. S. Madhavan as an Independent Director for a five-year term starting November 15, 2026.
Procter & Gamble Health held its 59th Annual General Meeting on September 3, 2026, where shareholders discussed financial results and directorial appointments.
Procter & Gamble Health Limited has filed its Business Responsibility & Sustainability Report for the financial year ended March 31, 2026.
Procter & Gamble Health Ltd has rescheduled its 59th AGM to September 3, 2026. The record date for the final dividend and AGM is August 27, 2026.
Procter & Gamble Health reported a 7% increase in quarterly sales to ₹356 crore. Profit After Tax rose 45% to ₹96 crore, aided by asset sale proceeds.
Procter & Gamble Health Ltd reported revenue from operations of ₹363.7 Cr (+7.4% YoY) and net profit of ₹96.2 Cr (+45.3% YoY) for Q1 FY27.
Procter & Gamble Health Limited declared a final dividend of Rs. 45 per share for the fiscal year 2025-2026. The record date is set for August 27, 2026.
Procter & Gamble Health rescheduled its 59th AGM to September 3, 2026. The record date for final dividend is now August 27, 2026.
Procter & Gamble Health scheduled a board meeting for August 6, 2026. The meeting will consider unaudited financial results for the June quarter.
Procter & Gamble Health announced senior management changes effective July 1, 2026. Updates include role changes and the appointment of Mr. Shine Matthew Sunny.
Procter & Gamble Health Limited submitted its Annual Secretarial Compliance Report for FY 2025-26. The report notes an inadvertent delay in disclosing a director's appointment.
Procter & Gamble Health re-appointed Subramanian Madhavan as Independent Director for a five-year term. The board-approved move ensures leadership continuity through November 2031.
Procter & Gamble Health recommended a final dividend of ₹45 per equity share for FY 2025-26. The record date for payment is fixed as August 21, 2026.
Procter & Gamble Health set August 21, 2026, as the record date for dividend payment. The dividend remains subject to shareholder approval at the August AGM.
Procter & Gamble Health re-appointed Mr. S. Madhavan as Independent Director for five years starting November 2026. The move ensures leadership continuity and board stability.
Procter & Gamble Health reported FY26 sales of ₹1385 Crore and PAT of ₹327 Crore. The Board recommended a final dividend of ₹45 per share.
Procter & Gamble Health Ltd reported revenue from operations of ₹370.4 Cr (+19.1% YoY) and net profit of ₹94.6 Cr (+54.6% YoY) for Q4 FY26.
Procter & Gamble Health reported a ₹449.86 Crore profit before tax for FY2026. The board recommended a ₹45 per share dividend, reflecting strong annual performance.
Procter & Gamble Health Limited has executed a sale agreement for immovable properties in Mumbai. The transaction is expected to generate a profit of approximately ₹32 Crore for the company.
Procter & Gamble Health Ltd confirmed it does not qualify as a 'Large Corporate' under the SEBI framework for the financial year. The company reported zero outstanding borrowings as of March 31, 2026, and is therefore not subject to mandatory incremental borrowing through debt securities.
Procter & Gamble Health Ltd submitted its quarterly certificate under Regulation 74(5) of SEBI (DP) Regulations for the period ended March 31, 2026. The filing confirms that security dematerialisation details have been furnished to stock exchanges. This is a routine regulatory compliance matter with no direct financial impact.